Avextra Portugal has launched an innovative in-house breeding program aimed at developing proprietary cannabis varieties with consistent cannabinoid and terpene profiles, crucial for pharmaceutical production and clinical research. Over the next two years, the program will utilize 5,000 seeds to conduct a comprehensive phenohunt, having already processed 600 seeds. Led by industry veterans, including former GW Pharmaceuticals Director Alan Sutton and genetics expert Steven Tan, the initiative seeks to stabilize plant intellectual property and optimize cultivation for effective therapeutic formulations. This breeding program represents a key component of Avextra’s intellectual property strategy, reinforcing its commitment to advancing safe and effective cannabis-based medicines that address the complex needs of patients.